IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,American ,Laurence Watts ,Gina Nugent ,Brett Hall ,American Association For Cancer Research ,Immuneering Corporation ,Immuneering Corporation Nasdaq ,Exchange Commission ,American Association ,Cancer Research ,Annual Meeting ,Chief Scientific Officer ,Deep Cyclic Inhibition ,Deep Cyclic Inhibitor ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,